{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:25:52Z","timestamp":1773271552053,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":4634,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1111\/j.1538-7836.2010.03737.x","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T10:25:50Z","timestamp":1262773550000},"page":"641-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding"],"prefix":"10.1016","volume":"8","author":[{"given":"S.","family":"SCHULMAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.A.","family":"SPENCER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMe020097","article-title":"Antithrombotic therapy after myocardial infarction","volume":"347","author":"Becker","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0015","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMe068061","article-title":"The charisma of subgroups and the subgroups of CHARISMA","volume":"354","author":"Pfeffer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0020","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehm326","article-title":"Aggressive antiplatelet strategies: time to reconsider?","volume":"28","author":"Serebruany","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST\u2010elevation myocardial infarction (TRITON\u2010TIMI 38): double\u2010blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(09)61454-9","article-title":"Otamixaban for the treatment of patients with non\u2010ST\u2010elevation acute coronary syndromes (SEPIA\u2010ACS1 TIMI 42): a randomised, double\u2010blind, active\u2010controlled, phase 2 trial","volume":"374","author":"Sabatine","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS\u2010TIMI 46): a randomised, double\u2010blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0045","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0055","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0060","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(03)12712-2","article-title":"Acute myocardial infarction","volume":"361","author":"Boersma","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0065","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0070","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0075","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta\u2010analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low\u2010dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0085","doi-asserted-by":"crossref","first-page":"b4531","DOI":"10.1136\/bmj.b4531","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: meta\u2010analysis of randomised controlled trials","volume":"339","author":"De Berardis","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0090","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low\u2010intensity oral anticoagulation with warfarin and low\u2010dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0100","first-page":"CD005158","article-title":"Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease","author":"Keller","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0105","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2007.11.057","article-title":"Meta\u2010analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events","volume":"101","author":"Bowry","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta\u2010analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0735-1097(00)01118-9","article-title":"Effects of long\u2010term, moderate\u2010intensity oral anticoagulation in addition to aspirin in unstable angina","volume":"37","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0125","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non\u2010Q\u2010wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial","volume":"89","author":"Cohen","year":"1994","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0135","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low\u2010molecular\u2010weight heparin in acute coronary syndrome without ST elevation: a meta\u2010analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0140","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0145","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non\u2010ST\u2010segment elevation acute coronary syndromes: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Harrington","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0150","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.CIR.100.20.2049","article-title":"Clinical outcomes of bivalirudin for ischemic heart disease","volume":"100","author":"Kong","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0155","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.100.20.2045","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibition in non\u2010ST\u2010elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention","volume":"100","author":"Boersma","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0160","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17\u2003187 cases of suspected acute myocardial infarction: ISIS\u20102","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0165","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","article-title":"ISIS\u20102: 10\u2003year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS\u20102 (Second International Study of Infarct Survival) Collaborative Group","volume":"316","author":"Baigent","year":"1998","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0170","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45\u2003852 patients with acute myocardial infarction: randomised placebo\u2010controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0175","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST\u2010segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0180","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.313.7058.652","article-title":"Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials","volume":"313","author":"Collins","year":"1996","journal-title":"BMJ"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0185","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1161\/CIRCULATIONAHA.105.573550","article-title":"Unfractionated and low\u2010molecular\u2010weight heparin as adjuncts to thrombolysis in aspirin\u2010treated patients with ST\u2010elevation acute myocardial infarction: a meta\u2010analysis of the randomized trials","volume":"112","author":"Eikelboom","year":"2005","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"Effects of reviparin, a low\u2010molecular\u2010weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST\u2010segment elevation","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0195","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low\u2010molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta\u2010analysis","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0200","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.jacc.2007.01.092","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST\u2010segment elevation myocardial infarction also treated with clopidogrel","volume":"49","author":"Sabatine","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0205","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST\u2010segment elevation myocardial infarction: the OASIS\u20106 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0210","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition: the GUSTO V randomised trial","volume":"357","author":"Topol","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0215","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","article-title":"A randomized comparison of coronary\u2010stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators","volume":"331","author":"Fischman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0220","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic\u2010drug regimens after coronary\u2010artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0225","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary\u2010artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon\u2010expandable\u2010stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group","volume":"331","author":"Serruys","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0235","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0735-1097(01)01713-2","article-title":"Meta\u2010analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting","volume":"39","author":"Bhatt","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0245","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.CIR.101.6.590","article-title":"A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary\u2010artery stents","volume":"101","author":"Muller","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0250","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1161\/CIRCULATIONAHA.104.532242","article-title":"Safety of coronary sirolimus\u2010eluting stents in daily clinical practice: one\u2010year follow\u2010up of the e\u2010Cypher registry","volume":"113","author":"Urban","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long\u2010term clinical outcomes after drug\u2010eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0260","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta\u2010analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0270","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1074248407306589","article-title":"Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions","volume":"12","author":"Singh","year":"2007","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0275","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0280","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0285","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0290","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/07853890802089786","article-title":"Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation","volume":"40","author":"Rubboli","year":"2008","journal-title":"Ann Med"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0295","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","article-title":"Safety and efficacy of combined antiplatelet\u2010warfarin therapy after coronary stenting","volume":"28","author":"Karjalainen","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0305","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/j.1538-7836.2008.03080.x","article-title":"Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide","volume":"6","author":"Jamula","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0310","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1540-8159.2008.02247.x","article-title":"Postoperative low\u2010molecular\u2010weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators","volume":"32","author":"Robinson","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1111\/j.1538-7836.2010.03737.x_bb0315","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/europace\/eup212","article-title":"Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation","volume":"11","author":"Cheng","year":"2009","journal-title":"Europace"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2010.03737.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622113103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622113103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2010.03737.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:51:49Z","timestamp":1761533509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622113103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1538783622113103"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03737.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03737.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}